VTv Therapeutics Current Ratio 2014-2021 | VTVT

VTv Therapeutics current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
VTv Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.01B $0.01B 2.23
2021-03-31 $0.01B $0.01B 1.79
2020-12-31 $0.01B $0.01B 1.13
2020-09-30 $0.00B $0.01B 0.44
2020-06-30 $0.01B $0.01B 0.59
2020-03-31 $0.00B $0.01B 0.29
2019-12-31 $0.00B $0.01B 0.21
2019-09-30 $0.00B $0.01B 0.25
2019-06-30 $0.00B $0.02B 0.22
2019-03-31 $0.01B $0.02B 0.33
2018-12-31 $0.00B $0.02B 0.18
2018-09-30 $0.01B $0.03B 0.23
2018-06-30 $0.01B $0.03B 0.19
2018-03-31 $0.01B $0.03B 0.35
2017-12-31 $0.02B $0.03B 0.76
2017-09-30 $0.02B $0.01B 1.76
2017-06-30 $0.03B $0.01B 2.95
2017-03-31 $0.05B $0.01B 4.14
2016-12-31 $0.05B $0.01B 4.56
2016-09-30 $0.05B $0.01B 4.93
2016-06-30 $0.06B $0.01B 6.54
2016-03-31 $0.08B $0.01B 8.88
2015-12-31 $0.09B $0.01B 11.54
2015-09-30 $0.10B $0.01B 16.10
2015-06-30 $0.00B $0.06B 0.04
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2013-12-31 $0.00B $0.09B 0.03
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.142B $0.006B
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71